Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis
Muscle & Nerve · 2024
DOI: 10.1002/mus.28227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, 2024. Verfasst von Yu-Fang Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Clinical Neurophysiology, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Myasthenia Gravis, Receptors, Cholinergic, Complement Activation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Erling-Persson Foundation, Swedish Research Council, Vetenskapsrådet.
Abstract (Originalsprache)
Introduction/Aims There are no blood biomarkers to monitor treatment effects in myasthenia gravis (MG) or studies visualizing the acetylcholine receptor (AChR) antibody‐induced membrane attack complex (MAC) at the human muscle membrane. This study aimed to compare levels of complement activation products and native complement components in MG patients and healthy controls (HCs) and to model the AChR antibody‐mediated attacks in human muscle cells.
Methods
We assessed the complement components and activation product levels with enzyme‐linked immunosorbent assay and magnetic bead‐based sandwich assays in plasma and sera of 23 MG patients and matched HCs. Receiver operator characteristic (ROC) curve analysis evaluated the diagnostic accuracy. Complement levels were correlated with the myasthenia gravis composite (MGC) scores. AChR+ MG modeling in human muscle cells used sera from nine MG patients and three HCs.
Results
MG patients had significantly higher plasma levels of C3a ( p < .0001), C5 ( p = .0003), and soluble C5b‐9 (sC5b‐9; p < .0001) than HCs. The ROC curve analysis showed a clear separation between MG patients and HCs for plasma C3a (AUC = 0.9720; p < .0001) and sC5b‐9 (AUC = 0.8917, p < .0001). MG patients had higher levels of plasma complement Factor I (FI; p = .0002) and lower properdin levels ( p < .0001). The MGC had moderate correlations with plasma Factor B (FB), FI, and Factor H. AChR+ MG patient sera triggered the deposition of MAC and reduced AChRs.
Discussion
We suggest validating plasma C3a and sC5b‐9 as blood biomarkers for complement activation in MG. Further, the in vitro study allowed visualization of MAC deposition after applying AChR+ MG sera on human muscle cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Clinical Neurophysiology, Uppsala University, Uppsala, Sweden.
- Linnaeus Center of Biomaterials Chemistry, Linnaeus University, Kalmar, Sweden.
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Förderung
- Erling-Persson Foundation
- Swedish Research Council
- Vetenskapsrådet
Zitieren
APA
Huang, Y. F., Sandholm, K., Persson, B., Nilsson, B., & Punga, A. R. (2024). Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis. Muscle & Nerve. https://doi.org/10.1002/mus.28227
Vancouver
Huang YF, Sandholm K, Persson B, Nilsson B, Punga AR. Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis. Muscle & Nerve. 2024. doi:10.1002/mus.28227
BibTeX
@article{Huang2024,
author = {Huang, Yu-Fang and Sandholm, Kerstin and Persson, Barbro and Nilsson, Bo and Punga, Anna Rostedt},
title = {Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis},
journal = {Muscle & Nerve},
year = {2024},
doi = {10.1002/mus.28227}
}
EUVIMED